Algethami Abdulmohsin K, Alshareef Alhusain M, Alhawsawi Waseem K, Bader Bader A, Alharbi Arwa, Alahmadi Raneem, Alsatti Hanadi, Abualola Amal H, Alqahtani Raneem
Dermatology, King Abdulaziz Medical City, Jeddah, SAU.
Dermatology, King Fahad Military Medical Complex, Jeddah, SAU.
Cureus. 2024 Jun 13;16(6):e62293. doi: 10.7759/cureus.62293. eCollection 2024 Jun.
Cyclin-dependent kinase (CDK) 4 and 6 inhibitors, such as palbociclib, have emerged as essential in managing hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. While effective, these inhibitors can cause rare dermatologic side effects, including vitiligo-like depigmentation. We report a rare case of a 52-year-old female with HR+, HER2- metastatic breast cancer who developed vitiligo-like depigmentation following palbociclib treatment. The patient presented with asymptomatic depigmented lesions on the lower limbs and abdomen, appearing seven months after starting palbociclib. Examination and investigations confirmed the diagnosis after excluding other potential causes. Despite treatment with topical steroids and calcineurin inhibitors, there was no significant improvement, highlighting the need for more research into effective management strategies for drug-induced vitiligo. This case emphasizes the importance of recognizing rare dermatologic side effects of CDK4/6 inhibitors like palbociclib. Ongoing vigilance, reporting, and research are necessary to improve understanding and management of these side effects, ultimately enhancing patient care in oncology.
细胞周期蛋白依赖性激酶（CDK）4和6抑制剂，如哌柏西利，已成为治疗激素受体阳性（HR+）、人表皮生长因子受体2阴性（HER2-）晚期或转移性乳腺癌的关键药物。虽然这些抑制剂有效，但可能会引起罕见的皮肤副作用，包括白癜风样色素脱失。我们报告了一例罕见病例，一名52岁的HR+、HER2-转移性乳腺癌女性在接受哌柏西利治疗后出现了白癜风样色素脱失。患者在开始使用哌柏西利七个月后，下肢和腹部出现无症状色素脱失性皮损。经过检查和调查，排除其他潜在病因后确诊。尽管使用了外用类固醇和钙调神经磷酸酶抑制剂治疗，但病情无明显改善，这凸显了对药物性白癜风有效管理策略进行更多研究的必要性。该病例强调了认识到像哌柏西利这样的CDK4/6抑制剂罕见皮肤副作用的重要性。持续的警惕、报告和研究对于增进对这些副作用的理解和管理是必要的，最终可改善肿瘤学领域的患者护理。
